ArticleBMC cancer2009
Do serum biomarkers really measure breast cancer?
Article in BMC cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Serum Analysis of Women with Early-Stage Breast Cancer Using a Mini-Array of Tumor-Associated Antigens.Biosensors · 2020Article
- Serum Health Biomarkers in African and Asian Elephants: Value Ranges and Clinical Values Indicative of the Immune Response.Animals : an open access journal from MDPI · 2020Article
- Prognostic value of biomarkers EpCAM and αB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis.BMC cancer · 2019Article
- Myeloperoxidase as an Active Disease Biomarker: Recent Biochemical and Pathological Perspectives.Medical sciences (Basel, Switzerland) · 2018Review
- Albumin and hemoglobin adducts of estrogen quinone as biomarkers for early detection of breast cancer.PloS one · 2018Article
- Emerging proteomics biomarkers and prostate cancer burden in Africa.Oncotarget · 2017Review
- Article
- Macrophage migration inhibitory factor involvement in breast cancer (Review).International journal of oncology · 2015Review
- Early detection of breast cancer using total biochemical analysis of peripheral blood components: a preliminary study.BMC cancer · 2015Article
- Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Article
- Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer.Oncology reports · 2014Article
- Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma.Molecular & cellular proteomics : MCP · 2014Article
- Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma.Metabolomics : Official journal of the Metabolomic Society · 2013Article
- Identification of a mimotope for circulating anti-cytokeratin 8/18 antibody and its usage for the diagnosis of breast cancer.International journal of oncology · 2013Article
- Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Macrophage migration inhibitory factor (MIF): a promising biomarker.Drug news & perspectives · 2010Review
- -The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.The International journal of biological markersReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundBecause screening mammography for breast cancer is less effective for premenopausal women, we investigated the feasibility of a diagnostic blood test using serum proteins.
methodsThis study used a set of 98 serum proteins and chose diagnostically relevant subsets via various feature-selection techniques. Because of significant noise in the data set, we applied iterated Bayesian model averaging to account for model selection uncertainty and to improve generalization performance. We assessed generalization performance using leave-one-out cross-validation (LOOCV) and receiver operating characteristic (ROC) curve analysis.
resultsThe classifiers were able to distinguish normal tissue from breast cancer with a classification performance of AUC = 0.82 +/- 0.04 with the proteins MIF, MMP-9, and MPO. The classifiers distinguished normal tissue from benign lesions similarly at AUC = 0.80 +/- 0.05. However, the serum proteins of benign and malignant lesions were indistinguishable (AUC = 0.55 +/- 0.06). The classification tasks of normal vs. cancer and normal vs. benign selected the same top feature: MIF, which suggests that the biomarkers indicated inflammatory response rather than cancer.
conclusionOverall, the selected serum proteins showed moderate ability for detecting lesions. However, they are probably more indicative of secondary effects such as inflammation rather than specific for malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.